SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of  Cellular Biomedicine Group, Inc. (Nasdaq – CBMG)  

BALA CYNWYD – August 13, 2020 /Access Wire/ – Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Cellular Biomedicine Group, Inc. (“CBMG” or the “Company”) (Nasdaq – CBMG) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the agreement to enter into an interested-party acquisition of CBMG by an entity consisting of a consortium including the Company’s CEO Bizuo (Tony) Liu, certain members of Company’s management, and certain stockholders and equity investors (the “Buyers”).  Under the terms of the agreement, CBMG shareholders will receive $19.75 in cash for each share they own.

The investigation concerns whether the CBMG Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether the Buyers are underpaying for the Company.

If you own shares of CBMG stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 805, Bala Cynwyd, PA 19004, or call toll free 877-534-2590.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.